Articles
| Open Access |
https://doi.org/10.5281/zenodo.20002409
ADVANCES IN REGIONAL CHEMOTHERAPY: A TARGETED APPROACH TO CANCER TREATMENT
Dr. AMAN KHANDELWAL , Assistant Teacher, Samarkand state medical university, Uzbekistan Wafa Shamsudheen , Medical Student, Samarkand state medical university, Uzbekistan Hadhi Zubair , Medical Student, Samarkand state medical university, Uzbekistan, Riyana Sherin , Medical Student, Samarkand state medical university, UzbekistanAbstract
Regional chemotherapy delivers cytotoxic agents directly to tumor-bearing regions while minimizing systemic exposure. This review examines HIPEC, HAI, TACE, PIPAC, and ILP modalities. Achieving locoregional drug concentrations 15–20× higher than systemic administration, these techniques enhance tumoricidal efficacy with reduced toxicity. Recent 2026 advances include molecular profiling integration, nanoparticle delivery, and combination immunotherapy. Clinical evidence demonstrates significant survival benefits in colorectal peritoneal metastases, hepatocellular carcinoma, and melanoma.
Keywords
regional chemotherapy, HIPEC, TACE, HAI, PIPAC, targeted drug delivery, peritoneal carcinomatosis, hepatocellular carcinoma, cytoreductive surgery, nanoparticle delivery
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020. CA Cancer J Clin. 2021;71:209-249.
Franko J, Shi Q, Meyers JP, et al. Prognosis of Peritoneal Metastatic CRC. Lancet Oncol. 2016;17:1709-1719.
Segelman J, Granath F, Holm T, et al. Risk Factors for Peritoneal Carcinomatosis. Br J Surg. 2012;99:699-705.
Cook AD, Single R, McCahill LE. Resection in Stage IV CRC. Ann Surg Oncol. 2005;12:637-645.
Booking Health. New Treatments for Stage 4 Cancer in 2026. 2026.
Alyami M, Hübner M, Grass F, et al. PIPAC: Rationale and Evidence. Lancet Oncol. 2019;20:e368-e377.
Dakwar GR, Shariati M, Willaert W, et al. Nanomedicine Intraperitoneal Therapy. Adv Drug Deliv Rev. 2017;108:13-24.
González-Moreno S. HIPEC: Rationale and Technique. World J Gastrointest Oncol. 2010;2:68.
Verwaal VJ, Van Ruth S, De Bree E, et al. Randomized Trial of CRS/HIPEC. J Clin Oncol. 2003;21:3737-3743.
Verwaal VJ, Bruin S, Boot H, et al. 8-Year Follow-up of HIPEC Trial. Ann Surg Oncol. 2008;15:2426-2432.
Quénet F, Elias D, Roca L, et al. PRODIGE 7 Phase 3 Trial. Lancet Oncol. 2021;22:256-266.
Berger Y, Schuitevoerder D, Vining CC, et al. Iterative HIPEC. Ann Surg Oncol. 2021;28:1777-1785.
Kemeny N, Huang Y, Cohen AM, et al. Hepatic Arterial Infusion. N Engl J Med. 1999;341:2039-2048.
Kemeny NE, Gonen M. HAI Response Rates. N Engl J Med. 2005;352:734-735.
DʼAngelica MI, Correa-Gallego C, Paty PB, et al. HAI Conversion to Resection. Ann Surg. 2015;261:353-360.
Douillard JY, Oliner KS, Siena S, et al. Panitumumab and RAS. N Engl J Med. 2013;369:1023-1034.
Lammer J, Malagari K, Vogl T, et al. PRECISION V DEB-TACE. Cardiovasc Intervent Radiol. 2010;33:41-52.
Llovet JM, Real MI, Montaña X, et al. Embolisation vs Symptomatic Treatment in HCC. Lancet. 2002;359:1734-1739.
Sacco R, Bargellini I, Bertini M, et al. TACE vs DEB-TACE. Expert Rev Gastroenterol Hepatol. 2021;15:1027-1039.
Solass W, Kerb R, Murdter T, et al. Pressurized Aerosol Chemotherapy. Ann Surg Oncol. 2014;21:553-559.
Rovers KP, Wassenaar ECE, Lurvink RJ, et al. CRC-PIPAC Phase II. Ann Surg Oncol. 2021;28:5311-5326.
Orgad R, Bakrin N, Bonnefoy I, et al. PIPAC Treatments and Survival. Ann Surg. 2026;283:505-512.
Raoof M, Whelan RL, Sullivan KM, et al. PIPAC Phase I USA. Ann Surg Oncol. 2023;30:7814-7824.
Thompson JF, Kam PC, Waugh RC, et al. Isolated Limb Infusion. Semin Surg Oncol. 1998;14:238-247.
Kroon HM, Moncrieff M, Kam PC, et al. Isolated Limb Infusion for Melanoma. Ann Surg Oncol. 2019;26:2101-2109.
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.